Drug Profile
Sm p80
Alternative Names: SchistoShield; Sm-p80Latest Information Update: 23 Jun 2022
Price :
$50
*
At a glance
- Originator Texas Tech University Health Sciences Center
- Developer National Institute of Allergy and Infectious Diseases; PAI Life Sciences
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Schistosomiasis
Most Recent Events
- 31 May 2022 Phase-I clinical trials in Schistosomiasis (Prevention) in Burkina Faso (IM) (NCT05762393)
- 31 May 2022 Phase-I clinical trials in Schistosomiasis (Prevention) in Madagascar (IM) (NCT05762393)
- 31 May 2022 PAI Life Sciences plans efficacy trials for Schistosomiasis (Prevention) in Netherlands and Uganda in 2023